Form 4: OptimizeRx CCO Granted Equity Awards

OptimizeRx Chief Commercial Officer Theresa Greco received 15,625 restricted stock units and 35,156 stock options as part of her compensation.

Summary

• Theresa Greco, Chief Commercial Officer of OptimizeRx Corp (OPRX), was granted 15,625 shares of common stock in the form of Restricted Stock Units (RSUs) on August 21, 2025.
• These RSUs were acquired at a price of $0 and will vest in three equal annual installments, commencing on August 21, 2026.
• Additionally, Ms. Greco was granted 35,156 stock options on August 21, 2025, with an exercise price of $16.14 per share.
• The stock options will also vest in three equal annual installments, beginning on August 21, 2026, and have an expiration date of August 21, 2030.
• Following these transactions, Ms. Greco beneficially owns 75,981 shares of common stock and 35,156 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The filing reflects a routine executive compensation event, which is generally neutral to slightly positive as it aligns management incentives with shareholder interests. It does not present new material information that would significantly alter the company's outlook.

Positives

• The equity grants align the Chief Commercial Officer's interests with those of shareholders, incentivizing long-term performance.
• The awards serve as a retention mechanism for a key executive, ensuring continuity in leadership.

Negatives

• The future vesting and exercise of these awards could lead to minor share dilution for existing shareholders.

Future Outlook

The vesting schedules for the restricted stock units and stock options indicate a future commitment to the Chief Commercial Officer, with awards becoming exercisable or convertible into shares over the next three years, starting in August 2026.

Industry Context

Executive equity grants, such as restricted stock units and stock options, are standard compensation practices across the healthcare technology and broader corporate sectors. These awards are designed to attract, retain, and motivate key personnel by linking their compensation to the company's long-term performance and shareholder value creation.

Stakeholder Impact

• Shareholders: Potential for minor future dilution upon vesting and exercise of equity awards, but also benefit from incentivized executive performance.
• Employees (Executive): Theresa Greco receives significant equity compensation, aligning her financial interests with the company's long-term success and providing a retention incentive.

Next Steps

• The restricted stock units and stock options will vest in three equal annual installments, with the first vesting occurring on August 21, 2026.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation in the form of equity grants. While these grants align management incentives with shareholder interests, they do not introduce new material information or significant operational changes that would warrant an alteration to an existing investment thesis. Therefore, a 'hold' recommendation is appropriate as the filing does not provide a basis for a 'buy' or 'sell' decision.

Keywords

OptimizeRx, OPRX, Theresa Greco, Chief Commercial Officer, Restricted Stock Units, Stock Options, Executive Compensation, Insider Transaction, Equity Grant